跳至主要内容
临床试验/NL-OMON49145
NL-OMON49145撤回3 期

Continuous low dose subcutaneous lidocaine for treatment of the symptoms of COVID*19.   A randomised controlled open*label phase III study. - Not applicable

Julius Clinical0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
撤回
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Each patient (or the patient*s legally authorized representatives) must sign
  • an informed consent form (ICF) indicating that they understand the purpose of
  • and procedures required for this study, are willing to participate in the study
  • and attend all scheduled visits, and are willing and able to comply with all
  • study-related procedures, and adhere to the prohibitions and restrictions as
  • specified in the protocol.
  • 2. Age >=18 years.
  • 3. Acute disease with a positive test for COVID-19.
  • 4. Patients with symptoms of COVID-19 admitted to the ICU, the hospital ward or
  • residing in a nursing home are eligible for inclusion in the study. Should a
  • patient with spontaneous breathing deteriorate requiring mechanical ventilation
  • after the inclusion the patient will remain in the study.

排除标准

  • 1. Patients known with allergy or hypersensitivity to lidocaine, xylocaine or
  • lignocaine.
  • 2. Patients with severe hypoalbuminaemia (decreased drug-protein binding),
  • 3. Patients with potentially reduced elimination speed of lidocaine:
  • a. Severe liver and kidney dysfunction
  • b. Use of certain medications: erythromycin, beta-blockers, ciprofloxacin,
  • cimetidine, clonidine, amiodarone or phenytoin.

研究者

发起方
Julius Clinical

相似试验

Continuous low dose subcutaneous... | 临床试验